Karen S. Lynch's Insider Trades & SAST Disclosures
Karen S. Lynch's most recent trade in Thermo Fisher Scientific Inc. was a trade of 95 Common Stock done . Disclosure was reported to the exchange on Feb. 19, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Karen S. Lynch.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 95 | 95 (0%) | 0% | 0 | Common Stock | |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 188,087 | 188,087 | - | - | Stock Option | |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 61,953 | 74,687 (0%) | 0% | 79.6 | 4,928,981 | Common Stock |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 79.56 per share. | 01 Apr 2024 | 45,248 | 45,248 | - | 79.6 | 3,599,931 | Common Stock (Restricted) |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 69.75 per share. | 03 May 2023 | 14,000 | 431,392 (0%) | 0% | 69.8 | 976,567 | Common Stock (By Trust) |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 244,952 | 244,952 | - | - | Stock Option | |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 93,677 | 112,933 (0%) | 0% | 74.3 | 6,961,138 | Common Stock |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 206,610 | 206,610 (0%) | 0% | 0 | Common Stock | |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 171,517 | 171,517 | - | - | Stock Option | |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 116,940 | 210,090 (0%) | 0% | 101.1 | 11,821,465 | Common Stock |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 257,916 | 327,030 (0%) | 0% | 0 | Common Stock | |
| U.S. Bancorp. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 13 | 7,796 | - | - | Deferred Compensation Plan Participation | |
| CVS Health Corp | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.52 per share. | 28 Nov 2021 | 14,121 | 69,114 (0%) | 0% | 91.5 | 1,292,354 | Common Stock |
| U.S. Bancorp. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2021 | 1,211 | 7,669 | - | - | Deferred Compensation Plan Participation | |
| U.S. Bancorp. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2021 | 2,849 | 2,849 | - | - | Restricted Stock Units | |
| CVS Health Corp | Karen S. Lynch | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 224,604 | 224,604 | - | - | Stock Option | |
| CVS Health Corp | Karen S. Lynch | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 95,302 | 95,302 (0%) | 0% | 0 | Common Stock | |
| CVS Health Corp | Karen S. Lynch | EVP and President, Aetna | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 43,211 | 52,091 (0%) | 0% | 74.3 | 3,210,577 | Common Stock |
| U.S. Bancorp. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2020 | 33 | 6,365 | - | - | Deferred Compensation Plan Participation | |
| CVS Health Corp | Karen S. Lynch | EVP and President, Aetna | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.63 per share. | 02 Dec 2020 | 12,779 | 94,370 (0%) | 0% | 69.6 | 889,802 | Common Stock |
| U.S. Bancorp. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 3,196 | 3,196 | - | - | Restricted Stock Units | |
| U.S. Bancorp. | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 2,098 | 6,216 | - | - | Deferred Compensation Plan Participation | |
| CVS Health Corp | Karen S. Lynch | EVP & Pres, Aetna Bus Unit | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2020 | 211,196 | 211,196 | - | - | Stock Option |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges